FDA is requesting a total budget of $8.4 billion as part of the president’s fiscal year 2023 budget—a nearly 34% ($2.1 billion) increase over the agency’s FY 2022 appropriated funding level—for investments in critical public health modernization, core food safety and medical product safety programs, and other public health infrastructure.Â
Researchers from VCU Massey Cancer Center, the University of Florida College of Medicine, and UF Health Cancer Center found that minority patient participation in cancer clinical trials is low—in part due to standard clinical trial criteria that disproportionately exclude Black patients.
Researchers at Fox Chase Cancer Center who looked at over 34,000 colorectal cancer patients found that certain PTEN mutations occur in distinct patterns in specific subsets of colorectal cancer.Â
An analysis by Yale Cancer Center researchers identified accelerated genetic aging in breast tissue adjacent to breast cancer tumors.Â
Researchers at Fox Chase Cancer Center identified several characteristics of papillary renal neoplasm with reverse polarity, a neoplasm that may simply be monitored rather than removed through surgery.
Genentech announced that the phase III SKYSCRAPER-02 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) and chemotherapy (carboplatin and etoposide) as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), did not meet its co-primary endpoint of progression-free survival.Â
Positive top-line data from the monotherapy arm of the ATHENA (GOG 3020/ENGOT-ov45) trial (ATHENA-MONO) demonstrated that Rubraca (rucaparib) as maintenance treatment achieved the primary endpoint of significantly improved investigator-assessed progression-free survival compared with placebo.Â
The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Keytruda (pembrolizumab), an anti-PD-1 therapy, in combination with chemotherapy and with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumors express PD-L1 (CPS ≥1).
The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of Cabometyx (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine, who have progressed during or after prior systemic therapy.
The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the European Commission to approve Kymriah (tisagenlecleucel), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
